Malaysia
Search
Sign In
Product Highlight - VIACORAM
16 Jun 2021
• First line indication for newly diagnosed hypertensive1
• Significant BP reduction with Viacoram in 4 weeks over monotherapies2,3
• Edema is 3X less common with Viacoram than with amlodipine mono-component2
• Clinically developed and proven for an easy start, rapid effect onset and favorable safety in newly diagnosed hypertensive2
References:
1. Viacoram SmPC
2. Laurent S et al. J Hypertens, 2015;33:653-662. International, randomized, double-blind, placebo-controlled study. Primary endpoint=BP lowering efficacy. An international, randomized, double-blind, placebo-controlled study with six equal parallel treatment arms and an 8-week randomized treatment period, whose design, clinical significance and non-inferiority criteria were in accordance with European guidelines. Objective: To evaluate perindopril 3.5 mg/amlodipine, 2.5 mg once daily, a novel fixed-dose combination adapted for first-step treatment in patients with hypertension.
3. Sub-analysis of an international, randomized, double-blind, placebo-controlled study with parallel treatment arms at 4 weeks. It has been focused on first-line treatment approved for hypertension: perindopril 3.5 mg/amlodipine 2.5 mg, perindopril 5 mg, amlodipine 5 mg, and placebo. Orginal Study, Laurent S et al. J Hypertens. 2015;33(3):653-662. An international, randomized, double-blind, placebo-controlled study with six equal parallel treatment arms and an 8-week randomized treatment period, whose design, clinical significance and non-inferiority criteria were in accordance with European guidelines.
• Significant BP reduction with Viacoram in 4 weeks over monotherapies2,3
• Edema is 3X less common with Viacoram than with amlodipine mono-component2
• Clinically developed and proven for an easy start, rapid effect onset and favorable safety in newly diagnosed hypertensive2
References:
1. Viacoram SmPC
2. Laurent S et al. J Hypertens, 2015;33:653-662. International, randomized, double-blind, placebo-controlled study. Primary endpoint=BP lowering efficacy. An international, randomized, double-blind, placebo-controlled study with six equal parallel treatment arms and an 8-week randomized treatment period, whose design, clinical significance and non-inferiority criteria were in accordance with European guidelines. Objective: To evaluate perindopril 3.5 mg/amlodipine, 2.5 mg once daily, a novel fixed-dose combination adapted for first-step treatment in patients with hypertension.
3. Sub-analysis of an international, randomized, double-blind, placebo-controlled study with parallel treatment arms at 4 weeks. It has been focused on first-line treatment approved for hypertension: perindopril 3.5 mg/amlodipine 2.5 mg, perindopril 5 mg, amlodipine 5 mg, and placebo. Orginal Study, Laurent S et al. J Hypertens. 2015;33(3):653-662. An international, randomized, double-blind, placebo-controlled study with six equal parallel treatment arms and an 8-week randomized treatment period, whose design, clinical significance and non-inferiority criteria were in accordance with European guidelines.